-
May 07, 2013
AbbVie has been boosted by the news that regulators in the USA have agreed to fast-track its closely-watched oral hepatitis C treatment
Full story
-
May 02, 2013
The European Medicines Agency has published on its website the final advice from the five multi-stakeholder advisory groups set up to consider various aspects of clinical-data transparency.
Full story
-
May 01, 2013
The European Medicines Agency (EMA) has been ordered by the General Court of the European Union (EU) not to provide documents as part of two access-to-documents requests until the Court gives a final ruling.
Full story
-
April 29, 2013
In its first quarter as an independent company, AbbVie has posted a strong set of financials as sales of its anti-inflammatory blockbuster Humira continued to soar
Full story
-
March 11, 2013
In a move which appears at odds with a push for transparency within the pharmaceutical industry, AbbVie is suing the European Medicines Agency to prevent it from releasing data related to its blockbuster Humira
Full story
-
January 24, 2013
Abbott Laboratories has presented combined financials for its existing business and the now-separate AbbVie division which show that growth was driven again by the anti-inflammatory blockbuster Humira
Full story
-
January 03, 2013
The biopharm company AbbVie has been officially launched after splitting from Abbott
Full story
-
November 29, 2012
Abbott's Board OK's cleaving off its research arm and declares a special dividend distributing the outstanding shares of the new entity's common stock.
Full story
-
November 06, 2012
As it prepares to complete the split of the company, Abbott Laboratories has completed a huge debt issue ahead of the creation of the AbbVie pharmaceuticals business
Full story
-
July 19, 2012
Abbott Laboratories has posted a decent set of financials for the second quarter, driven again by its anti-inflammatory blockbuster Humira
Full story